Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses

• Autor(a) principal: Melo, Raul Emrich [UNIFESP]
• Data de Publicação: 2003
• Outros Autores: Solé, Dirceu [UNIFESP], Naspitz, Charles Kirov [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://repositorio.unifesp.br/handle/11600/27122; http://dx.doi.org/10.1067/mai.2003.66
• topic: exercise-induced asthma; late phase; montelukast; leukotrienes; Children

Background: Montelukast, a leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. We and others have shown that there is a late-phase response 3 to 8 hours after exercise in a subset of asthmatic patients.Objective: We sought to evaluate the protective effect of montelukast on immediate-phase and late-phase responses after exercise challenges.Methods: Twenty-two atopic asthmatic children aged 7 to 16 years with reproducible exercise-induced bronchoconstriction (minimum of 15% decrease of FEV1 from baseline) were enrolled in this placebo-controlled crossover study. Exercise challenges were performed while breathing cold dry air, and FEV1 measurements were taken up to 480 minutes after exercise. Patients underwent exercise challenges on a screening day and 1 week after placebo treatment. Subsequently, after a week with no treatment, pulmonary function was assessed after breathing dry cold air (control day). Finally, an exercise challenge was carried out after a week of treatment with montelukast.Results: Reproducible late-phase reactions occurred in 5 of 22 patients, which correlated with the extent of the immediate response (P <.05). After 1 week of treatment with montelukast, a significant decrease of immediate responses was observed. Montelukast treatment compared with placebo was associated with a lower mean maximum decrease of FEV1 (mean SEM: 17.3% +/- 2.4% and 35.1% +/- 2.6%, respectively), decrease of the area above the curve (267.8% +/- 42.7%/min and 868.0% +/- 103.8%/min, respectively), and shorter time for recovery (6.9 +/- 1.1 minutes and 30.9 +/- 4.0 minutes, respectively; P < .05). Treatment with montelukast also abolished latephase responses.Conclusion: Once daily treatment with oral montelukast attenuated the immediate-phase response and abolished the latephase response induced by means of exercise challenge in asthmatic children. (J Allergy Clin Immunol 2003;111:301-7.).